Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
The clear cell renal cell carcinoma (CRCC) is the most common cáncer of the kidney, at the time of diagnosis 30% of patients have metastases and 40% are in disease recurrence. It is highly resistant to chemotherapy and poor responses were evidenced with the interleukins and interferón before use, so that the current target therapy with tyrosine kinase inhibitors were used.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cáncer statistics, 2002. C A Cáncer J Clin 2005;55:74-108
American Cáncer Society: Cáncer Facts and Figures 2012. Atlanta GACS, 2012. Avaible at: www.cancer.org/acs/
groups/contení/@ epidem iologysurveilance/docum ents/document/acspc-031941 -pdf
Karumanchí SA, MerchanJ and SukhatmeVP. Renal cáncer molecular mechanism and newer therapeutic options. Curr Opin Nephrol Hypertens 2012;11:37-42. Avaible at: www.ncbi.nlm.nih.gov/pubmed/11753085
- Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cáncer] Sci A m 2000;6:Suppl 1-.S55-S57
- McDermott DF, Regan MM, Clark Jl, et al. Randomized phase III tria/ of high-dose interleukin-2 versus subcutaneous interleukin-2 and Ínterferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:l33-141[Erratum, ] Clin Oncol 2005;23:2877.]
- Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. N at Genet
;7:85-90
Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275
N C C N Guidelines Versión 1.2013 Kidney Cáncer. Avaible at: www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
- Heng DY, Xie W, Harschman LC, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec ¡;27(341:5794-5799. Avaible at: www.ncbi.nlm.nih.gov/pubmed/19826129
Flaningan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastasic renal cáncer: a combined analysis. J Urol2004; 171:1071-1076. Avaible at:http://www.ncbi.nlm.nih.gov/pubmed/14767273
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon in metastatic renal-cell carcinoma. N Engl J Med 2007; 358:115-124. Avaible at: www.ncbi.nlm.nih.gov/pubmed/17215529
- Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JA M A 2006;295:2516 2524
Motzer RJ, HutsonTE, Tomczac P, et al. Overall survival and uptdate results for sunitinib compared with interferon alga in patientes with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590. Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/19487381
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of S U 11248, a multitarged inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24- Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/16330672
- YangJC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cáncer. J Clin Oncol 2003;21:3127-3132
- Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU 11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cáncer Res 2003;9:327-337
Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extensión of the Memorial Sloan-Kettering prognostic factors modelfor survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-841
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferón alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d 'inmunetherapie. N Engl J Med 1998,338: 1272-1278. Avaible at: http://www.ncbi.nlm.nih.gov/pubmed/9562581
- Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cáncer. Cochrane Database Syst Rev 2005;l:CD001425-CD00l425 Medline
- Heng DYC, Xie W, Harshman LC, et al. Extemanl validation of International Metastasic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy (abstract). J Clin Oncol 2011; 29(15_suppl): Abstract 4560. Available at: http://meeting.ascopubs.org/cgi/content/abstract/2915supll/4560
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.